Literature DB >> 2095339

The haemodynamic effects of long term felodipine therapy in previously untreated essential hypertension.

S Capewell1, C G Wathen, W J Hannan, A L Muir.   

Abstract

Sixteen patients with previously untreated mild/moderate hypertension (WHO Stage I) were studied: 7 women and 9 men, mean age 56.2 y. Haemodynamics, central and pulmonary blood volumes were measured by radionuclide techniques and repeated after 8 weeks felodipine therapy. To achieve a target diastolic blood pressure of less than 95 mm Hg 12 patients required 5 mg bid, 2 10 mg bid and 1 2.5 mg bid; 1 withdrew after 2 weeks. Mean (SD) arterial blood pressure (mm Hg) was 189/106 before, and 182/103 after 2 weeks placebo treatment and fell to 148/84 after 8 weeks felodipine therapy. Relative systemic vascular resistance fell by 19% from 2146 to 1734 dyn.s.cm-5. There were no significant changes in heart rate, cardiac index, total blood volume, pulmonary blood volume or left ventricular ejection fraction. Plasma renin activity did not rise significantly. Short lived vasodilator side effects occurred in 7/16 patients during initial treatment and mild ankle oedema persisted in 4/16 patients. In contrast to the haemodynamic changes seen acutely with felodipine, the only sustained changes after 8 weeks therapy are reductions in systemic vascular resistance and blood pressure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095339     DOI: 10.1007/bf00316091

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

Review 1.  Second messengers in renin secretion.

Authors:  P C Churchill
Journal:  Am J Physiol       Date:  1985-08

2.  Felodipine monotherapy in hypertension.

Authors:  W A Littler; S A Smith; P J Mace
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Lack of effect of nifedipine on counterregulatory mechanisms in essential hypertension.

Authors:  N E Bruun; H Ibsen; F Nielsen; M D Nielsen; A G Moelbak; O J Hartling
Journal:  Hypertension       Date:  1986-08       Impact factor: 10.190

4.  The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease.

Authors:  A C Tweddel; G Johnsson; T H Pringle; R G Murray; I Hutton
Journal:  Eur Heart J       Date:  1983-10       Impact factor: 29.983

5.  A radionuclide method for the simultaneous study of the effects of drugs on central and peripheral haemodynamics.

Authors:  C G Wathen; W J Hannan; C J Adie; A L Muir
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

Review 6.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

7.  A microassay for active and total renin concentration in human plasma based on antibody trapping.

Authors:  J A Millar; B J Leckie; J J Morton; J Jordan; M Tree
Journal:  Clin Chim Acta       Date:  1980-02-14       Impact factor: 3.786

8.  Hemodynamic effects of verapamil in essential hypertension at rest and during exercise.

Authors:  P Lund-Johansen
Journal:  Acta Med Scand Suppl       Date:  1984

9.  Radionuclide assessment of peripheral intravascular capacity: a technique to measure intravascular volume changes in the capacitance circulation in man.

Authors:  D L Rutlen; F J Wackers; B L Zaret
Journal:  Circulation       Date:  1981-07       Impact factor: 29.690

10.  Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.

Authors:  W Culling; M S Ruttley; D J Sheridan
Journal:  Br Heart J       Date:  1984-10
View more
  2 in total

Review 1.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 2.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.